M
IMEPro
J67.9 Respiratory
Updated March 2026

Hypersensitivity pneumonitis due to unspecified organic dust

ICD-10 Code: J67.9 · Body Part: Head/Brain (TBI)

QME Evaluation Process

PFTs, DLCO, high-resolution CT, serology for precipitins, exposure history. Chapter 5 respiratory impairment.

Typical Impairment Rating

10-40% WPI based on PFT impairment

AMA Guides Edition

5th Edition

Common Treatments

+ Antigen avoidance
+ Corticosteroids for acute
+ Immunosuppressants for chronic
+ Pulmonary rehabilitation

Related Conditions

Body Part Guide

Head/Brain (TBI) Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Hypersensitivity pneumonitis due to unspecified organic dust

Find a QME Specialist

Browse QME-certified physicians who evaluate hypersensitivity pneumonitis due to unspecified organic dust and related head/brain (tbi) conditions in California.

Browse Neurology Physicians →

Frequently Asked Questions

What is Hypersensitivity pneumonitis due to unspecified organic dust (J67.9)?

Hypersensitivity pneumonitis due to unspecified organic dust is an ICD-10 diagnosis code (J67.9) classified under Respiratory conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is J67.9 rated for impairment?

The typical whole person impairment (WPI) range for Hypersensitivity pneumonitis due to unspecified organic dust is 10-40% WPI based on PFT impairment. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for J67.9?

PFTs, DLCO, high-resolution CT, serology for precipitins, exposure history. Chapter 5 respiratory impairment.

What treatments are common for Hypersensitivity pneumonitis due to unspecified organic dust?

Common treatments for Hypersensitivity pneumonitis due to unspecified organic dust include Antigen avoidance, Corticosteroids for acute, Immunosuppressants for chronic, Pulmonary rehabilitation. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.